Yuki N, Hayashi N, Kasahara A, Katayama K, Ueda K, Fusamoto H, Kamada T
First Department of Medicine, Osaka University Medical School, Japan.
Hepatology. 1990 Aug;12(2):193-8. doi: 10.1002/hep.1840120203.
We have studied antibodies (anti-pol antibody) against the polymerase gene product of hepatitis B virus by solid-phase enzyme immunoassay using synthetic peptides coded for by this gene. Sera from six patients with acute hepatitis B, 112 chronic hepatitis B virus carriers and six healthy individuals with naturally acquired immunity to hepatitis B virus were tested for anti-pol antibody. In acute hepatitis B virus infection, anti-pol antibody was detected in three of six patients. In chronic hepatitis B virus infection, anti-pol antibody was detected in 17 of 29 (59%), in 23 of 33 (70%) of cirrhotic patients and in 18 of 24 (75%) patients with cirrhosis complicated by hepatocellular carcinoma, compared with 4 of 19 (21%) asymptomatic carriers and 2 of 7 (29%) patients with chronic persistent hepatitis. Titers of anti-pol antibody were higher in cirrhotic patients with and without hepatocellular carcinoma than in patients with chronic active hepatitis. The presence of anti-pol antibody, however, had no relationship with hepatitis B virus-associated DNA polymerase activities and other viral replicative markers. As for sera from six healthy individuals with naturally acquired immunity to hepatitis B virus, two (33%) were positive for anti-pol antibody. These results indicate that the immune response toward the polymerase gene product is induced during acute and chronic hepatitis B virus infection. In chronic hepatitis B virus infection, anti-pol antibody may serve as a new marker indicative of a long period of hepatitis B virus-induced hepatitis.
我们使用该基因编码的合成肽，通过固相酶免疫测定法研究了针对乙型肝炎病毒聚合酶基因产物的抗体（抗聚合酶抗体）。检测了6例急性乙型肝炎患者、112例慢性乙型肝炎病毒携带者以及6例对乙型肝炎病毒具有自然获得性免疫力的健康个体血清中的抗聚合酶抗体。在急性乙型肝炎病毒感染中，6例患者中有3例检测到抗聚合酶抗体。在慢性乙型肝炎病毒感染中，29例中有17例（59%）、肝硬化患者33例中有23例（70%）以及肝硬化合并肝细胞癌患者24例中有18例（75%）检测到抗聚合酶抗体，相比之下，19例无症状携带者中有4例（21%）以及7例慢性持续性肝炎患者中有2例（29%）检测到该抗体。有或无肝细胞癌的肝硬化患者中抗聚合酶抗体滴度均高于慢性活动性肝炎患者。然而，抗聚合酶抗体的存在与乙型肝炎病毒相关的DNA聚合酶活性及其他病毒复制标志物无关。至于6例对乙型肝炎病毒具有自然获得性免疫力的健康个体的血清，2例（33%）抗聚合酶抗体呈阳性。这些结果表明，在急性和慢性乙型肝炎病毒感染期间会诱导针对聚合酶基因产物的免疫反应。在慢性乙型肝炎病毒感染中，抗聚合酶抗体可能作为乙型肝炎病毒所致肝炎病程较长的一种新标志物。
